TY - JOUR ID - TI - EVALUATION OF CHANGES IN THE LEVELS OF PROSTATE SPECIFIC ANTIGEN (PSA) AND PROSTATIC ACID PHOSPHATASE IN PATIENTS PRESENTING WITH URINARY RETENTION AND PROSTATE DISEASE AU - Firas Shakir Attar* PY - 2009 VL - 27 IS - 2 SP - 108 EP - 112 JO - The Medical Journal of Basrah University المجلة الطبية لجامعة البصرة SN - 02530759 AB - ABSTRACTProstate specific antigen (PSA) has established itself as the most useful marker for adenocarcinoma of the prostate(ADCA) adenocarcinoma of the prostate and in the recent years has almost replaced the total acid phosphatase andprostatic acid phosphatase prostatic acid phosphatase (PAP) for screening, diagnosis and monitoring the prostatecarcinoma patients. The prostate specific antigen levels also rise in benign prostatic hypertrophy benign prostatichypertrophy but to a lesser extent and high values are usually diagnostic of malignant disease. A cross-sectionalcomparative study was planned to see the effect of urinary retention and catheterization on plasma concentration ofadenocarcinoma of the prostate and prostatic acid phosphatase and the value of this effect in the diagnosis of patientsas having benign prostatic hypertrophy or adenocarcinoma of prostate. Sixty patients with prostatic disease wereincluded in the study. Adenocarcinoma of the prostate and prostatic acid phosphatase levels were assessed in allpatients. The patients were divided into two groups; group I are those presented with urinary retention andcatheterization and group II those presented without urinary retention (without catheter). Following histologicalexamination of prostatic tissues, the patients were diagnosed as cases of benign prostatic hyperplasia oradenocarcinoma of prostate. The data were analyzed using t-test. Benign prostatic hypertrophy was detected in 48patients whereas 12 patients were diagnosed with adenocarcinoma of the prostate. In the study, 66.2% of benignprostatic hypertrophy and 50% of adenocarcinoma of the prostate patients presented with urinary retention andcatheterization. It was observed that prostate specific antigen levels were significantly raised in benign prostaticpatients with urinary retention and catheterization as compared to those with no retention. There was, however, nosignificant rise in prostatic acid phosphatase levels in those patients. In conclusion, prostatic acid phosphatase is stilla very good tumor marker of prostatic disease in differentiating the malignant from the benign disease. It appears tobe particularly important in patients with benign prostatic hyperplasia and urinary retention as catheterizationappears to raise significantly the levels of prostate specific antigen but not those of prostatic acid phosphates. Thisfinding means that patients presenting with urinary retention and catheterization and high prostatic acid phosphateslevels are more likely having carcinoma of the prostate because retention and catheterization don’t significantly raisethe prostatic acid phosphates levels in benign prostatic hypertrophy as they raise prostate specific antigen levels insuch patients.

ER -